endocrine therapy with aromatase inhibitors (AIs) for women with hormone receptorpositive breast cancer is a prime example. Although some data support AI use for 5 years based on randomized clinical trials, evidence is still unclear beyond this duration, and
Search Results
Jonas A. de Souza, Mark J. Ratain, and A. Mark Fendrick
Crystal S. Denlinger, Jennifer A. Ligibel, Madhuri Are, K. Scott Baker, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Lee Jones, Allison King, Grace H. Ku, Elizabeth Kvale, Terry S. Langbaum, Kristin Leonardi-Warren, Mary S. McCabe, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Mary Ann Morgan, Javid J. Moslehi, Tracey O’Connor, Linda Overholser, Electra D. Paskett, Muhammad Raza, Karen L. Syrjala, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Nicole McMillian, and Deborah Freedman-Cass
breast surgery and 50% in those treated with lung surgery. 1 Arthralgias, characterized by joint pain and stiffness, occur in roughly half of women taking aromatase inhibitors as adjuvant therapy for breast cancer. 15 Pelvic pain often occurs after
Robert W. Carlson, Susan Moench, Arti Hurria, Lodovico Balducci, Harold J. Burstein, Lori J. Goldstein, William J. Gradishar, Kevin S. Hughes, Mohammad Jahanzeb, Stuart M. Lichtman, Lawrence B. Marks, Joan S. McClure, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Mary Lou Smith, Neal S. Topham, Tiffany A. Traina, John H. Ward, and Eric P. Winer
aromatase inhibitors. 27 , 28 Life Expectancy Estimation of survival was identified by many task force participants as a key factor in making treatment decisions for older women with breast cancer. Data from the U.S. Centers for Disease Control and
Metastatic Breast Cancer, Version 1.2012
Featured Updates to the NCCN Guidelines
Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, Stephen B. Edge, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Steven Jay Isakoff, Britt-Marie E. Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, Hatem Soliman, George Somlo, Richard L. Theriault, John H. Ward, Antonio C. Wolff, Richard Zellars, Rashmi Kumar, and Dorothy A. Shead
postmenopausal women with hormone receptor–positive advanced breast cancer that had progressed or recurred during treatment with a nonsteroidal aromatase inhibitor randomized patients to exemestane with or without the mTOR inhibitor everolimus. 17 The results of
Cindy Railton, Sasha Lupichuk, Jennifer McCormick, Lihong Zhong, Jenny Jaeeun Ko, Barbara Walley, Anil A. Joy, and Janine Giese-Davis
to aromatase inhibitors (AIs). Analysis To summarize demographic, chart review, pharmacy, and interview data, we used descriptive statistics, SAS 9.3, and 2-tailed tests. Using chi-square and Fisher exact tests, we compared PCP versus cancer
Therese B. Bevers
aromatase inhibitors (AIs) exemestane and anastrozole have shown even greater breast cancer risk reduction for women at increased risk of developing the disease. 5 , 6 However, the trials were small and these agents are not currently FDA-approved for this
Scott Ramsey and Veena Shankaran
: 36 – 46 . 23 Sedjo RL Devine S . Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer . Breast Cancer Res Treat 2011 ; 125 : 191 – 200 . 24 Kelley RK Venook AP
Somasundaram Subramaniam, Jason A. Zell, and Pamela L. Kunz
improving progression-free survival in patients with hormone receptor-positive advanced breast cancer previously treated with nonsteroidal aromatase inhibitors. Common side effects of everolimus include stomatitis, rash, diarrhea, fatigue, and upper
Julia C. Shih and Anthony J. Olszanski
. 6 Within cancer care, the earliest reports of nonadherence rates were documented in breast cancer with endocrine therapies, ranging from 12% to 59% with tamoxifen and 9% to 50% with aromatase inhibitors. 7 In a systematic review by Greer et al, 1
Azeez Farooki
with various cancer therapies, including aromatase inhibitor (AI) therapy in postmenopausal women and AI therapy and gonadotropin-releasing hormone (GnRH) agonists in pre-menopausal women with breast cancer, bone marrow transplantation in patients with
